The label expansion comes three years after the FDA signed off on Nubeqa in combination ... With Nubeqa and kidney disease treatment Kerendia—which achieved an 89% increase in sales to 161 ...

Kerendia (finerenone) is the first drug in its class to show a benefit ... Bayer is running an open-label study – CONFIRMATION-HF – testing Kerendia with Jardiance in patients hospitalised ...

However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by ...

Before we present a few large drug stocks that are well-positioned ... Bayer is also working to expand the labels of Nubeqa and Kerendia, which, if successful, can further drive growth.

The data will be filed with regulatory authorities to seek an expansion of the label for Nubeqa, according to Bayer, which developed Nubeqa in collaboration with Finland's Orion. The drug is ...

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a ...

KERENDIA is a non-steroidal mineralocorticoid receptor antagonist (MRA) and was approved by the U.S. Food and Drug Administration (FDA) in July 2021 to reduce the risk of sustained eGFR decline ...

Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...

"Higher doses can produce euphoria, and some countries have restricted how tianeptine is prescribed and dispensed or revised the drug label to warn of possible addiction," Makary said. "FDA ...

That percentage is 22 times larger than the rate that is currently listed on the drug’s FDA label. Researchers have cast doubt on the study. One aspect of the study that has come under scrutiny ...